Country: Ирска
Језик: Енглески
Извор: HPRA (Health Products Regulatory Authority)
Tiamulin hydrogen fumarate
Huvepharma NV
QJ01XQ01
Tiamulin hydrogen fumarate
125 milligram(s)/millilitre
Oral solution
POM: Prescription Only Medicine as defined in relevant national legislation
Pigs
tiamulin
Antibacterial
Authorised
2010-02-05
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Vetmulin 125 mg/ml Oral Solution for use in drinking water for pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCE Tiamulin hydrogen fumarate 125 mg (equivalent to 101.2 mg tiamulin) EXCIPIENTS Methyl parahydroxybenzoate (E218) 0.90 mg Propyl parahydroxybenzoate 0.10 mg For the full list of excipients: see section 6.1 3 PHARMACEUTICAL FORM Oral solution for use in drinking water. Clear colourless to slightly yellow liquid. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES In pigs For the treatment of swine dysentery caused by or further complicated by tiamulin-susceptible_ Brachyspira_ _hyodysenteriae._ For the treatment of enzootic pneumonia and the reduction of lesions caused by tiamulin-susceptible_ Mycoplasma_ _hyopneumoniae._ The presence of the disease in the herd should be established before use. 4.3 CONTRAINDICATIONS Do not use in animals with known hypersensitivity to the active substance or to any of the excipient. Do not use in the case of resistance to tiamulin. Do not administer products containing monensin, salinomycin, narasin, maduramicin or other ionophores during or for at least seven days before or after treatment with the product. See also section 5.1. and 4.8. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _0_ _3_ _/_ _0_ _5_ _/_ _2_ _0_ _1_ _7_ _C_ _R_ _N_ _ _ _7_ _0_ _2_ _5_ _5_ _3_ _9_ _p_ _a_ _g_ Прочитајте комплетан документ